Patents by Inventor John A. Beutler

John A. Beutler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287297
    Abstract: Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: May 14, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fundació Institut Català d'Investigació Quimica (ICIQ), Universitat Rovira i Virgili
    Inventors: John A. Beutler, Antonio M. Echavarren, Laura Lopez, Fernando Bravo, Lorena Riesgo, Tanya Tannaquil Ransom
  • Publication number: 20180127433
    Abstract: Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.
    Type: Application
    Filed: April 13, 2016
    Publication date: May 10, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Fundació Institut Català d'Investigació Química (ICIQ), Universitat Rovira i Virgili
    Inventors: John A. BEUTLER, Antonio M. ECHAVARREN, Laura LOPEZ, Fernando BRAVO, Lorena RIESGO, Tanya Tannaquil RANSOM
  • Patent number: 9676788
    Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: June 13, 2017
    Assignees: The United States of America, as represented by the Secretary of Health and Human Services, University of Hawaii
    Inventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
  • Patent number: 9517224
    Abstract: Disclosed is a method of activating protein kinase C theta (PKC?) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R1-R6 are described herein. Examples of diseases or conditions associated with PKC? include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: December 13, 2016
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Leonard M. Neckers, Carole Sourbier, Jane B. Neckers, Min-Jung Lee, John A. Beutler, W. Marston Linehan, Bradley T. Scroggins, Sunmin Lee
  • Publication number: 20160347764
    Abstract: Disclosed is a compound of formula (I) or formula (II): (Formulas should be inserted here) wherein R1-R6 are as defined herein. Also disclosed are a pharmaceutical composition comprising such a compound and a method of treating or preventing cancer in a mammal in need thereof, comprising administering to the mammal a compound of formula (I) or formula (II).
    Type: Application
    Filed: February 5, 2015
    Publication date: December 1, 2016
    Applicants: The United State of America, as represented by the Secretary, Department of Health and Human Service, University of Hawaii
    Inventors: William J. Chain, John A. Beutler, David Fash, William D. Figg, Zhenwu Li, Cody John Peer, Joe William Ramos, Florian J. Sulzmaier
  • Publication number: 20150283111
    Abstract: Disclosed is a method of activating protein kinase C theta (PKC?) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R1-R6 are described herein. Examples of diseases or conditions associated with PKC? include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 8, 2015
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Leonard M. Neckers, Carole Sourbier, Jane B. Neckers, Min-Jung Lee, John A. Beutler, W. Marston Linehan, Bradley T. Scroggins, Sunmin Lee
  • Patent number: 9101601
    Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 11, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
  • Patent number: 8993768
    Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John A. Beutler, Stuart F. J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
  • Publication number: 20140350093
    Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 27, 2014
    Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
  • Publication number: 20140249181
    Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).
    Type: Application
    Filed: May 10, 2012
    Publication date: September 4, 2014
    Applicant: The united States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: John A. Beutler, Stuart F.J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
  • Patent number: 8686016
    Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: April 1, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Iowa Research Foundation
    Inventors: Karlyne Reilly, Thomas Turbyville, John A. Beutler, David Wiemer
  • Patent number: 8410292
    Abstract: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2?-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: April 2, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John A. Beutler, Ranjala Ratnayake, David Covell, Tanya R. Johnson
  • Publication number: 20120095089
    Abstract: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula.
    Type: Application
    Filed: April 30, 2010
    Publication date: April 19, 2012
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Karlyne Reilly, Thomas Turbyville, John A. Beutler, David Wiemer
  • Publication number: 20110319481
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Application
    Filed: January 26, 2011
    Publication date: December 29, 2011
    Applicants: Government of the United States of America, National Institute of Health, University of Iowa Research Foundation
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Patent number: 7902228
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: March 8, 2011
    Assignees: University of Iowa Research Foundation, The United States of America, National Institute of Health
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Publication number: 20100286259
    Abstract: Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant Phyllanthus engleri or produced by synthetic methods. An example of the englerin derivative is 2?-chloroenglerin A, which has the structure (II), wherein double bond ‘a’ is E, Z, or a mixture of E and Z.
    Type: Application
    Filed: December 30, 2008
    Publication date: November 11, 2010
    Applicant: The US, DHHS, NIH
    Inventors: John A. Beutler, Ranjala Ratnayake, David Covell, Tanya R. Johnson
  • Publication number: 20080227852
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Application
    Filed: February 4, 2008
    Publication date: September 18, 2008
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Patent number: 7358377
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: April 15, 2008
    Assignees: University of Iowa Research Foundation, The United States of America
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Publication number: 20080015232
    Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.
    Type: Application
    Filed: March 29, 2005
    Publication date: January 17, 2008
    Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
  • Patent number: 6353019
    Abstract: The present invention provides compound of the formula: wherein R1 and R2 are the same or different and are independently H, C1-C6 straight-chain or branched saturated or unsaturated alkyl, aryl, R6CH2—, R6CO—, or R6SO2—, wherein R6 is H, C1-C6 straight-chain or branched saturated or unsaturated alkyl, or aryl; R3 is H, C1→C6 straight-chain or branched-chain saturated alkyl, aryl, an oxime, or an oxime methyl ether; at least one aromatic ring position is optionally substituted with a substituent selected from the group consisting of halo, nitro, amino, hydroxyl, thio, acyl, C1-C6 alkyl, and cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms (including heteroatoms) which atoms, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, which carbons are covalently bonded to either end of linker Z, integrally form a 12-15 membe
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: March 5, 2002
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, Tawnya C. McKee, John H. Cardellina, II, John A. Beutler, Karen Erickson, Deborah Galinis, Lewis Pannell